MRNA:NSD-Moderna Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 137.91

Change

0.00 (0.00)%

Market Cap

USD 54.86B

Volume

6.49M

Avg Analyst Target

USD 200.41 (+45.32%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Moderna Inc (MRNA) Stock Analysis:
Based on the Moderna Inc stock forecasts from 11 analysts, the average analyst target price for Moderna Inc is USD 200.41 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 137.91. Moderna Inc’s stock price has changed by +2.61% over the past week, -16.67% over the past month and -14.54% over the last year.

About

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD63.10B 27.38 17.74
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.40B 3.79 1.55
RPRX Royalty Pharma plc

N/A

USD26.93B 26.81 14.86
SGEN Seagen Inc

N/A

USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

N/A

USD18.31B 43.41 4.62
ARGX argenx SE

N/A

USD16.90B N/A N/A
INCY Incyte Corporation

N/A

USD16.59B 17.54 21.87

ETFs Containing MRNA

Symbol Name Weight Mer Price(Change) Market Cap
QBTL:CA AGFiQ US Market Neutral A.. 0.21 % 0.55 %

N/A

USD0.25B
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

N/A

USD0.44B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

N/A

USD0.20B
QQEQ:CA Invesco NASDAQ 100 Equal .. 0.00 % 0.25 %

N/A

N/A
BBIG:CA Horizons Global BBIG Tech.. 0.00 % 0.45 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.79 %

N/A

N/A
TECB iShares U.S. Tech Breakth.. 0.00 % 0.40 %

N/A

N/A
GERM ETF Managers Trust - ETFM.. 0.00 % 0.68 %

N/A

N/A
ZINN:CA BMO MSCI Innovation Index.. 0.00 % 0.40 %

N/A

N/A
FTGU:XETRA First Trust Global Funds .. 0.00 % 0.75 %

N/A

USD0.10B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.46B
XRSM:F Xtrackers (IE) Public Lim.. 0.00 % 0.02 %

N/A

USD0.11B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.45B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

N/A

USD0.46B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.37B
HWF:CA Middlefield Healthcare & .. 0.00 % 0.85 %

N/A

USD0.05B
BBP ETFis Series Trust I - Vi.. 0.00 % 0.79 %

N/A

USD0.01B
LS:CA Middlefield Healthcare & .. 0.00 % 0.85 %

N/A

USD0.08B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

USD0.05B
IUSS Invesco RAFI Strategic US.. 0.00 % 0.23 %

N/A

USD0.05B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

USD0.41B
SPMO Invesco S&P 500 Momentum .. 0.00 % 0.13 %

N/A

USD0.08B
MWD:CA Mackenzie Maximum Diversi.. 0.00 % 0.55 %

N/A

USD0.38B
MUS:CA Mackenzie Maximum Diversi.. 0.00 % 0.50 %

N/A

USD0.16B
IPO Renaissance IPO ETF 0.00 % 0.60 %

N/A

USD0.20B
IBB iShares Biotechnology ETF 0.00 % 0.45 %

N/A

USD7.49B
FLAG First Light Acquisition G.. 0.00 % 1.44 %

N/A

USD0.28B
FHH:CA First Trust AlphaDEX U.S... 0.00 % 0.77 %

N/A

USD0.02B
EUSA iShares MSCI USA Equal We.. 0.00 % 0.09 %

N/A

USD0.44B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.10B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.70% 53% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.70% 53% F 27% F
Trailing 12 Months  
Capital Gain -14.54% 87% B+ 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.54% 86% B 54% F
Trailing 5 Years  
Capital Gain 41,690.91% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 41,690.91% 100% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain 696.97% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 696.97% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,003.85% 3% F 2% F
Risk Adjusted Return 69.43% 96% A 89% B+
Market Capitalization 54.86B 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.87 55% F 84% B
Price/Book Ratio 2.88 29% F 29% F
Price / Cash Flow Ratio 4.03 7% F 42% F
EV/EBITDA 2.41 27% F 79% C+
Management Effectiveness  
Return on Equity 146.08% 99% A+ 99% A+
Return on Invested Capital 146.21% 98% A+ 98% A+
Return on Assets 51.93% 100% A+ 100% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.74 69% D+ 55% F
Short Percent 5.20% 46% F 33% F
Beta 1.54 36% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.